Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Politics : Formerly About Advanced Micro Devices -- Ignore unavailable to you. Want to Upgrade?

To: maceng2 who wrote (1462988)	6/15/2024 10:47:59 PM
From: Doren	1 Recommendation Recommended By pocotrader Read Replies (1) \| Respond to of 1572167

He took it voluntarily. Nobody put a gun to his head.

To: maceng2 who wrote (1462988)	6/15/2024 10:59:24 PM
From: Doren	Read Replies (1) \| Respond to of 1572167

4 could easily be within normal statistical aberration. Particularly as we don't know the number in this "trial" which trial it is or which vaccine she talks about or her full testimony. Once we have those numbers we can compare to the FDA trials. . . . Pfizer enrolled 46,331 people in the trial, with the majority of participants ranging from ages 16-56. Additional trial populations included people as young as 12 years old and people with chronic, stable human immunodeficiency virus (HIV), Hepatitis C virus (HCV), or Hepatitis B virus (HBV) infections.